742 related articles for article (PubMed ID: 24444383)
41. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
42. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
43. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
44. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
[TBL] [Abstract][Full Text] [Related]
45. Cell cycle inhibitors protect motor neurons in an organoid model of Spinal Muscular Atrophy.
Hor JH; Soh ES; Tan LY; Lim VJW; Santosa MM; Winanto ; Ho BX; Fan Y; Soh BS; Ng SY
Cell Death Dis; 2018 Oct; 9(11):1100. PubMed ID: 30368521
[TBL] [Abstract][Full Text] [Related]
46. CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.
Bisteau X; Paternot S; Colleoni B; Ecker K; Coulonval K; De Groote P; Declercq W; Hengst L; Roger PP
PLoS Genet; 2013 May; 9(5):e1003546. PubMed ID: 23737759
[TBL] [Abstract][Full Text] [Related]
47. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
48. Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors.
Fu Y; Tang S; Su Y; Lan X; Ye Y; Zha C; Li L; Cao J; Chen Y; Jiang L; Huang Y; Ding J; Geng M; Huang M; Wan H
Bioorg Med Chem Lett; 2017 Dec; 27(23):5332-5336. PubMed ID: 29074254
[TBL] [Abstract][Full Text] [Related]
49. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.
Cepeda D; Ng HF; Sharifi HR; Mahmoudi S; Cerrato VS; Fredlund E; Magnusson K; Nilsson H; Malyukova A; Rantala J; Klevebring D; Viñals F; Bhaskaran N; Zakaria SM; Rahmanto AS; Grotegut S; Nielsen ML; Szigyarto CA; Sun D; Lerner M; Navani S; Widschwendter M; Uhlén M; Jirström K; Pontén F; Wohlschlegel J; Grandér D; Spruck C; Larsson LG; Sangfelt O
EMBO Mol Med; 2013 Jul; 5(7):1067-86. PubMed ID: 23776131
[TBL] [Abstract][Full Text] [Related]
50. Adhesion-regulated G1 cell cycle arrest in epithelial cells requires the downregulation of c-Myc.
Benaud CM; Dickson RB
Oncogene; 2001 Jul; 20(33):4554-67. PubMed ID: 11494151
[TBL] [Abstract][Full Text] [Related]
51. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
52. p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs.
Prathapam T; Aleshin A; Guan Y; Gray JW; Martin GS
J Biol Chem; 2010 Oct; 285(42):32529-38. PubMed ID: 20647308
[TBL] [Abstract][Full Text] [Related]
53. Cell cycle regulation and apoptotic cell death in experimental colon carcinogenesis: intervening with cyclooxygenase-2 inhibitors.
Saini MK; Sanyal SN
Nutr Cancer; 2015; 67(4):620-36. PubMed ID: 25825916
[TBL] [Abstract][Full Text] [Related]
54. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
55. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
[TBL] [Abstract][Full Text] [Related]
56. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
[TBL] [Abstract][Full Text] [Related]
57. Fangchinoline induces G1 arrest in breast cancer cells through cell-cycle regulation.
Xing Z; Zhang Y; Zhang X; Yang Y; Ma Y; Pang D
Phytother Res; 2013 Dec; 27(12):1790-4. PubMed ID: 23401195
[TBL] [Abstract][Full Text] [Related]
58. Dual regulation of the anaphase promoting complex in human cells by cyclin A-Cdk2 and cyclin A-Cdk1 complexes.
Mitra J; Enders GH; Azizkhan-Clifford J; Lengel KL
Cell Cycle; 2006 Mar; 5(6):661-6. PubMed ID: 16582612
[TBL] [Abstract][Full Text] [Related]
59. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
60. Cyclin B1 interacts with the BH3-only protein Bim and mediates its phosphorylation by Cdk1 during mitosis.
Mac Fhearraigh S; Mc Gee MM
Cell Cycle; 2011 Nov; 10(22):3886-96. PubMed ID: 22071694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
